Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors.
作者信息
Pratt C B, Douglass E C, Meyer W H, Hayes F A, Horowitz M E, Thompson E I, Avery L
机构信息
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
出版信息
Invest New Drugs. 1989 Jul;7(2-3):209-11. doi: 10.1007/BF00170859.
PMID:2793374
Abstract
4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity. Maximum tolerated dosage was 36 mg/m2 given IV once every 3 weeks. Dose limiting toxicity was myelosuppression, which was severe and prolonged. Therapeutic benefits were not observed for these patients.
摘要
Zotero 插件